BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37986077)

  • 1. Comparison of clinical characteristics and prognosis in endometrial carcinoma with different pathological types: a retrospective population-based study.
    Zhang G; Nie F; Zhao W; Han P; Wen J; Cheng X; Wu W; Liu Q; Sun Y; Wang Y; Liu Y; Ren F
    World J Surg Oncol; 2023 Nov; 21(1):357. PubMed ID: 37986077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant therapy of uterine clear cell carcinoma: a review.
    Xu Y; Hanna RK; Elshaikh MA
    Arch Gynecol Obstet; 2016 Mar; 293(3):485-92. PubMed ID: 26626183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An analysis of current treatment practice in uterine papillary serous and clear cell carcinoma at two high volume cancer centers.
    Vogel TJ; Knickerbocker A; Shah CA; Schiff MA; Isacson C; Garcia RL; Goff BA
    J Gynecol Oncol; 2015 Jan; 26(1):25-31. PubMed ID: 25376917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemotherapy in patients with stage IVB uterine serous carcinoma: a Turkish multicentric study.
    Unsal M; Kilic C; Cakir C; Kilic F; Ersak B; Karakas S; Tokgozoglu N; Varli B; Oktar O; Kimyon Comert G; Ozdemir IA; Boran N; Toptas T; Ureyen I; Korkmaz V; Taskin S; Moraloglu Tekin O; Ustun Y; Tasci T; Ortac F; Turan T
    J Obstet Gynaecol; 2023 Dec; 43(1):2151355. PubMed ID: 36503383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological characteristics, treatment and outcomes in uterine carcinosarcoma and grade 3 endometrial cancer patients: a comparative study.
    Zhu J; Wen H; Bi R; Wu X
    J Gynecol Oncol; 2016 Mar; 27(2):e18. PubMed ID: 26463439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors and treatment outcomes for patients with surgically staged uterine clear cell carcinoma focusing on the early stage: A Taiwanese Gynecologic Oncology Group study.
    Hsu KF; Chou HH; Huang CY; Fu HC; Chiang AJ; Tsai HW; Chen JR; Cheng WF; Ke YM; Chang CC; Chen TH; Lin SH; Ho CM
    Gynecol Oncol; 2014 Sep; 134(3):516-22. PubMed ID: 25019570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diagnosis, treatment and prognosis of uterine serous carcinoma].
    Zhang F; Deng LS; Li B; Huang MN; Li XG; Zhang R; Wu LY
    Zhonghua Fu Chan Ke Za Zhi; 2020 Dec; 55(12):848-856. PubMed ID: 33355760
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience.
    Armbruster SD; Previs R; Soliman PT; Westin SN; Fellman B; Jhingran A; Fleming ND
    Gynecol Oncol; 2019 Aug; 154(2):328-332. PubMed ID: 31221496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uterine Clear Cell Carcinoma: Does Adjuvant Chemotherapy Improve Outcomes?
    Nguyen JM; Bouchard-Fortier G; Bernardini MQ; Atenafu EG; Han G; Vicus D; Ferguson SE; Gien LT
    Int J Gynecol Cancer; 2017 Jan; 27(1):69-76. PubMed ID: 27668398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overall and progression-free survival in endometrial carcinoma: A single-center retrospective study of patients treated between 2000-2018.
    Sait KH; Anfinan N; Sait H; Shamrani H; Sait M
    Ann Saudi Med; 2023; 43(5):315-328. PubMed ID: 37805818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemotherapy versus primary cytoreductive surgery for stage IV uterine serous carcinoma.
    Wilkinson-Ryan I; Frolova AI; Liu J; Stewart Massad L; Thaker PH; Powell MA; Mutch DG; Hagemann AR
    Int J Gynecol Cancer; 2015 Jan; 25(1):63-8. PubMed ID: 25365590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison.
    Zhang C; Hu W; Jia N; Li Q; Hua K; Tao X; Wang L; Feng W
    Int J Gynecol Cancer; 2015 May; 25(4):629-36. PubMed ID: 25633654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal cytoreduction, depth of myometrial invasion, and age are independent prognostic factors for survival in women with uterine papillary serous and clear cell carcinomas.
    Solmaz U; Mat E; Ekin A; Gezer C; Biler A; Peker N; Ayaz D; Sanci M
    Int J Surg; 2016 Aug; 32():71-7. PubMed ID: 27365052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The comparison of pure uterine serous carcinoma and mixed tumor with serous component: a single-institution review of 91 cases.
    You X; Dong Y; Wang J; Cheng Y; Jia Y; Zhang X; Wang J
    BMC Cancer; 2024 Jan; 24(1):99. PubMed ID: 38233757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinicopathologic and survival analysis of synchronous primary endometrial and ovarian cancer].
    Wang Y; Yu M; Yang JX; Cao DY; Zhang Y; Shen K; You Y
    Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):816-822. PubMed ID: 30585019
    [No Abstract]   [Full Text] [Related]  

  • 16. Optimal cytoreduction followed by chemoradiation in stage IVB uterine serous carcinoma.
    McEachron J; Zhou N; Hastings V; Bennett M; Gorelick C; Kanis MJ; Lee YC
    Cancer Treat Res Commun; 2022; 33():100631. PubMed ID: 36096033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival outcomes and the prognostic significance of clinicopathological features in patients with endometrial clear cell carcinoma: a 35-year single-center retrospective study.
    Ma X; Cao D; Zhou H; Wang T; Wang J; Zhang Y; Yu M; Cheng N; Peng P; Yang J; Huang H; Shen K
    World J Surg Oncol; 2023 Mar; 21(1):106. PubMed ID: 36973753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference?
    Boruta DM; Gehrig PA; Groben PA; Bae-Jump V; Boggess JF; Fowler WC; Van Le L
    Cancer; 2004 Nov; 101(10):2214-21. PubMed ID: 15452833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of clinical characteristics and prognosis between type I and type II endometrial cancer: a single-center retrospective study.
    Wang Y; Sun Y; Sun F; Han P; Fan R; Ren F
    Discov Oncol; 2023 Nov; 14(1):211. PubMed ID: 37994955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Lineage/Site-specific Nuclear Immunohistochemical Markers SATB2, Cyclin D1, SALL4, and BCOR in High-grade Endometrial Carcinomas.
    Dyhdalo KS; Ababneh E; Lanigan C; Bowers K; Zhang S; McKenney JK; Joehlin-Price AS
    Int J Gynecol Pathol; 2023 Sep; 42(5):443-450. PubMed ID: 36731037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.